Assembly Biosciences (ASMB) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bright Minds Biosciences (DRUG) has outperformed Assembly Biosciences (ASMB) over the past year, losing 5.8% versus a loss of 10.5%. Over five years, DRUG leads with a +40.0% price change compared with -41.7% for ASMB. Bright Minds Biosciences is the larger company by market cap ($533.2 million vs $479.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | DRUG |
|---|---|---|
| Share price | $23.53 | $54.05 |
| Market cap | $479.08M | $533.15M |
| 1-day change | +3.11% | +3.94% |
| YTD return | -32.90% | -33.37% |
| 1-year return | -10.51% | -5.80% |
| 5-year return | -41.67% | +39.97% |
| P/E ratio (TTM) | 22.63 | — |
| EPS (TTM) | $1.04 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.71 | $123.75 |
| 52-week low | $21.80 | $47.23 |
| Distance from 52-week high | -40.75% | -56.32% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +120.99% | +181.17% |
| Average volume | 279.78K | 159.01K |
| Shares outstanding | 20.36M | 9.86M |
| Employees | 73 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
ASMB vs DRUG FAQ
Which is bigger, Assembly Biosciences or Bright Minds Biosciences?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $533.15M compared with $479.08M for Assembly Biosciences (ASMB).
Which stock has performed better over the past year, ASMB or DRUG?
DRUG returned -5.80% over the past 12 months, compared with -10.51% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Bright Minds Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.